XGN
XGN
NASDAQ · Biotechnology

Exagen Inc

$2.95
+0.30 (+11.32%)
As of Mar 31, 3:11 PM ET ·
Financial Highlights (FY 2026)
Revenue
77.20M
Net Income
-23,134,389
Gross Margin
58.3%
Profit Margin
-30.0%
Rev Growth
+13.5%
D/E Ratio
1.49
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 58.3% 58.3% 59.0% 59.0%
Operating Margin -21.6% -19.4% -31.9% -26.3%
Profit Margin -30.0% -28.5% -24.3% -24.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 77.20M 68.03M 17.09M 20.29M
Gross Profit 44.99M 39.65M 10.08M 11.97M
Operating Income -16,659,859 -13,212,789 -5,444,397 -5,327,440
Net Income -23,134,389 -18,347,682 -4,142,594 -5,000,058
Gross Margin 58.3% 58.3% 59.0% 59.0%
Operating Margin -21.6% -19.4% -31.9% -26.3%
Profit Margin -30.0% -28.5% -24.3% -24.7%
Rev Growth +13.5% +13.5% +9.1% +5.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 21.54M 21.54M 33.95M 31.55M
Total Equity 14.46M 14.46M 108.93M 108.86M
D/E Ratio 1.49 1.49 0.31 0.29
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -15,947,079 -13,350,127 -7,262,848 -9,094,907
Free Cash Flow -5,494,601 -5,886,545